Asset profile
Pilavapadin
Small molecule
Evidence outlook · lead readout
NCT04455633 · Diabetic Peripheral Neuropathy, Diabetes
The completed lead evidence has the design features that historically survive confirmatory trials — randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT04455633: The study randomized 319 participants in a 1:1:1 ratio and used quadruple blinding with placebo control. The primary clinical pain endpoint was met for both dose regimens: average daily pain improved significantly more with LX9211 than placebo at the 100 mg/10 mg dose (p=0.007) and the 200 mg/20 mg dose (p=0.030).
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.